FY2024 Earnings Estimate for Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Issued By HC Wainwright

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Equities research analysts at HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a research note issued on Thursday, August 22nd. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.60) per share for the year, down from their prior estimate of ($0.59). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.79) per share.

Separately, Rodman & Renshaw initiated coverage on shares of Milestone Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $9.00 price objective on the stock.

Milestone Pharmaceuticals Stock Up 2.1 %

MIST opened at $1.47 on Monday. The company has a market cap of $78.29 million, a PE ratio of -1.18 and a beta of 1.64. The company has a quick ratio of 22.75, a current ratio of 22.75 and a debt-to-equity ratio of 1.27. The business has a 50 day moving average price of $1.42 and a two-hundred day moving average price of $1.56. Milestone Pharmaceuticals has a 52 week low of $1.12 and a 52 week high of $3.52.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its holdings in Milestone Pharmaceuticals by 177.0% in the first quarter. BNP Paribas Financial Markets now owns 16,900 shares of the company’s stock valued at $30,000 after purchasing an additional 10,800 shares during the period. BML Capital Management LLC lifted its stake in shares of Milestone Pharmaceuticals by 37.0% in the 1st quarter. BML Capital Management LLC now owns 606,145 shares of the company’s stock valued at $1,085,000 after purchasing an additional 163,793 shares in the last quarter. Finally, Lion Point Capital LP grew its holdings in shares of Milestone Pharmaceuticals by 1.7% during the 2nd quarter. Lion Point Capital LP now owns 2,340,207 shares of the company’s stock worth $3,089,000 after purchasing an additional 40,000 shares during the period. 86.18% of the stock is currently owned by institutional investors and hedge funds.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.